2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
- PMID: 31270974
- PMCID: PMC6609431
- DOI: 10.3348/kjr.2019.0140
2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
Abstract
Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection is high in middle-aged and elderly patients. These practice guidelines will provide useful and constructive advice for the clinical management of patients with HCC. A total of 44 experts in hepatology, oncology, surgery, radiology, and radiation oncology in the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2014 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions.
Keywords: Carcinoma, hepatocellular; Diagnosis; Guidelines; Management.
Copyright © 2019 The Korean Society of Radiology.
Conflict of interest statement
Conflicts of interests among the members are summarized in Supplementary Materials.
Figures





Similar articles
-
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.Clin Mol Hepatol. 2022 Oct;28(4):583-705. doi: 10.3350/cmh.2022.0294. Epub 2022 Oct 1. Clin Mol Hepatol. 2022. PMID: 36263666 Free PMC article.
-
2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.Gut Liver. 2019 May 15;13(3):227-299. doi: 10.5009/gnl19024. Gut Liver. 2019. PMID: 31060120 Free PMC article.
-
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.Korean J Radiol. 2022 Dec;23(12):1126-1240. doi: 10.3348/kjr.2022.0822. Korean J Radiol. 2022. PMID: 36447411 Free PMC article. Review.
-
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.J Liver Cancer. 2023 Mar;23(1):1-120. doi: 10.17998/jlc.2022.11.07. Epub 2022 Dec 9. J Liver Cancer. 2023. PMID: 37384024 Free PMC article. Review.
-
Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective.Clin Mol Hepatol. 2023 Apr;29(2):197-205. doi: 10.3350/cmh.2022.0404. Epub 2023 Jan 5. Clin Mol Hepatol. 2023. PMID: 36603575 Free PMC article. Review.
Cited by
-
Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification.Liver Cancer. 2024 Mar 12;13(5):561-571. doi: 10.1159/000538301. eCollection 2024 Oct. Liver Cancer. 2024. PMID: 39435269 Free PMC article.
-
Serum CYFRA 21-1 and CK19-2G2 as Predictive Biomarkers of Response to Transarterial Chemoembolization in Hepatitis C-related Hepatocellular Carcinoma Among Egyptians: A Prospective Study.J Clin Exp Hepatol. 2025 Jan-Feb;15(1):102405. doi: 10.1016/j.jceh.2024.102405. Epub 2024 Aug 17. J Clin Exp Hepatol. 2025. PMID: 39309220
-
Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma.BMC Gastroenterol. 2021 Jun 12;21(1):258. doi: 10.1186/s12876-021-01833-2. BMC Gastroenterol. 2021. PMID: 34118869 Free PMC article.
-
Intraindividual Comparison of MRIs with Extracellular and Hepatobiliary Contrast Agents for the Noninvasive Diagnosis of Hepatocellular Carcinoma Using the Korean Liver Cancer Association-National Cancer Center 2022 Criteria.Cancer Res Treat. 2023 Jul;55(3):939-947. doi: 10.4143/crt.2022.1645. Epub 2023 Feb 10. Cancer Res Treat. 2023. PMID: 36791769 Free PMC article.
-
Safety and Efficacy of Liver-Directed Radiotherapy in Combination With Lenvatinib for Hepatocelluar Carcinoma With Macroscopic Tumor Thrombosis.Front Oncol. 2022 May 11;12:888755. doi: 10.3389/fonc.2022.888755. eCollection 2022. Front Oncol. 2022. PMID: 35646674 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical